肝硬化中的肝肾综合征
本文综述肝硬化中肝肾综合征(HRS)的病理生理、新定义(急性HRS-AKI与慢性CKD)、鉴别诊断、治疗(血管收缩药联合白蛋白扩容)及预后,指出肝移植为理想根治手段,并强调预防、早期识别、生物标志物及治疗反应等未满足需求。
要点
- HRS分急性HRS-AKI与慢性CKD两型,HRS-AKI为肝硬化最严重AKI形式之一。
- HRS-AKI需与AKI-急性肾小管坏死鉴别,肾生物标志物可能有助。
- HRS-AKI治疗基于血管收缩药联合白蛋白扩容,理想根治为肝移植或肝肾联合移植。
核心结论
- HRS-AKI预后差,理想根治为肝移植或肝肾联合移植,其管理在酒精相关肝炎或代谢相关脂肪性肝病肝硬化等特定情况仍具挑战。
研究设计与样本
- 综述,检索范围未具体报告。
主要发现
- HRS由晚期肝硬化循环血流动力学改变引起肾功能显著受损,全身炎症和细菌易位可加重。
- HRS-AKI为肾功能突然受损,常由感染触发,出现于晚期失代偿肝硬化背景。
- HRS-AKI对患者生活质量有重大影响。
关键数值与推荐
- HRS-AKI治疗基于血管收缩药联合白蛋白扩容。
- HRS-AKI理想根治为肝移植或肝肾联合移植。
临床怎么用
- HRS-AKI需与其他AKI病因鉴别,因其需要特定治疗。
- 与AKI-急性肾小管坏死鉴别可能困难,肾生物标志物可能有助。
局限性
- HRS-AKI领域未满足需求包括:开发预防措施、改善早期识别、发现用于鉴别诊断的新生物标志物、改善治疗反应。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatorenal syndrome (HRS) is a form of kidney dysfunction that characteristically occurs in liver cirrhosis. It is characterized by a marked impairment of kidney function in response to circulatory and hemodynamic alterations that occur in advanced stages of liver cirrhosis, aggravated by systemic inflammation and bacterial translocation. The classical definitions of the types of HRS have been recently revisited and 2 forms of HRS have been redefined: the acute form, referred to as acute kidney injury (HRS-AKI), and the chronic form, referred to as chronic kidney disease. HRS-AKI is one of the most severe forms of AKI in patients with cirrhosis and it consists of an abrupt impairment of kidney function, frequently triggered by an infection, appearing in the setting of advanced decompensated cirrhosis. Differential diagnosis with other causes of AKI is crucial because HRS-AKI requires a specific treatment. Differential diagnosis with AKI-acute tubular necrosis may be challenging and kidney biomarkers may be useful in this setting. Treatment of HRS-AKI is based on the administration of vasoconstrictor drugs in combination with volume expansion with albumin. Prognosis of HRS-AKI is poor, and the ideal definitive treatment consists of liver transplantation or simultaneous liver-kidney transplantation. HRS-AKI has a big impact on patients' quality of life. Management of HRS-AKI remains challenging in specific situations such as alcohol-associated hepatitis or metabolic-associated steatotic liver disease cirrhosis. Developing preventive measures for HRS-AKI, improving its early identification, discovering new biomarkers for differential diagnosis, and improving the response to therapy are some of the unmet needs in the field of HRS-AKI.
引用
- Pose E, Piano S, Juanola A, et al. Hepatorenal Syndrome in Cirrhosis. Gastroenterology. 2024. PMID: 38246506. doi:10.1053/j.gastro.2023.11.306
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。